Engineered Clostridium bioprocess platform for high-titer renewable ester production
Engineered Clostridium bacteria by adding ester-forming enzymes and modifying metabolic genes to convert native alcohols, acids, and acyl‐CoAs into record‐high butyl acetate yields using CRISPR‐based genome editing and in situ solvent extraction.
Background
Microbial fermentation has emerged as a promising avenue for sustainable production of biofuels and biochemicals, driven by the need to reduce reliance on fossil resources and mitigate greenhouse gas emissions. Among these targets, fatty acid-derived esters such as butyl acetate offer high energy density, favorable hydrophobicity for phase separation, and utility as solvents and flavoring agents. Their potential for higher carbon yield and compatibility with existing infrastructure make them attractive candidates for next-generation renewable fuels and industrial chemicals. Rapidly increasing energy demands and stringent regulatory pressures further escalate the urgency for efficient bioprocess development. However, translating laboratory-scale biosynthesis into cost-competitive processes remains challenging due to the inherent limitations of microbial platforms under industrial conditions.
Current microbial approaches often suffer from severe product-induced stress, where accumulating solvents disrupt membrane integrity and metabolic balance, leading to low cell viability and stalled fermentations. Efforts to improve titers are hampered by poor tolerance thresholds, resulting in premature cessation of production and low volumetric productivity. Additionally, emulsification and the formation of complex broth matrices complicate downstream recovery, driving up separation energy and capital expenses. Coupled with limited carbon conversion efficiency and strain instability over prolonged cultivations, these factors inflate operational costs and impede commercial scalability.
Technology
The engineered Clostridium saccharoperbutylacetonicum N1-4-C strain incorporates four alcohol acyltransferases (vaat, saat, atf1, eht1) plus a lipaseB to drive ester formation directly from its native acyl-CoAs, alcohols and acids. Targeted deletions of the nuoG gene channel additional reducing power into product synthesis, while chromosomal integration of a sadh-hydG cluster via CRISPR-Cas9 redirects acetone flux to isopropanol, further pulling the pathway toward butyl acetate. By coupling these genetic modifications with in situ solvent extraction to mitigate product toxicity, the optimized strain achieves an unprecedented 34.8 g/L butyl acetate in extractive fermentation—the highest titer reported in a metabolically engineered microbe.
This platform is differentiated by its holistic rerouting of metabolic flux and innovative toxicity management. Instead of merely boosting precursor supply, it balances co-factor use and product recovery, leveraging isopropanol formation as a metabolic sink and extractive fermentation for seamless downstream separation. The strategy combines rational gene deletions, heterologous enzyme expression and chromosome-level pathway integration to outperform previous microbial systems, delivering both high yield and economic viability for sustainable ester bioproduction.
Benefits
- Record-breaking 34.8 g/L butyl acetate titer—the highest reported in a metabolically engineered microbe
- In situ solvent extraction alleviates product toxicity, enabling sustained high-yield fermentation
- CRISPR-Cas9–mediated genomic edits and strategic gene deletions optimize metabolic flux
- Production of a high-value, hydrophobic ester biofuel/chemical that’s easily recoverable
- Hydrophobic properties simplify downstream separation, reducing purification costs
- Economically competitive process (estimated $799/ton vs. $1,000–$1,300/ton market price)
Applications
- Bio-based industrial solvent production
- Food and beverage flavorings
- Cosmetic fragrance ingredient production
- Renewable biofuel blend components
- Pharmaceutical grade solvent manufacturing
Additional info
Clostridium saccharoperbutylacetonicum N1-4-C was reprogrammed via CRISPR-Cas9 to integrate four alcohol acyltransferases (vaat, saat, atf1, eht1) plus lipaseB, enabling direct esterification of native acyl-CoAs, alcohols and acids. Deletion of nuoG boosted NADH availability, and chromosomal insertion of a sadh-hydG cluster converted acetone to isopropanol. Coupled with in situ solvent extraction to mitigate toxicity, this strain produced 34.8 g/L butyl acetate.